Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval that could give patients a more convenient option of the widely used cancer drug.